Although mutant BRAF dominates any discussion about melanoma targets, activating mutations in the kinase occur only in 50% of patients, implying that other factors are at work. Researchers at Children's Hospital Boston and colleagues have used zebrafish models to identify two such factors: DHODH, an enzyme already being targeted for autoimmune diseases, and a histone methyltransferase called SETDB1. 1,2